CRANBURY, N.J.–(BUSINESS WIRE)–#AJMC—The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, presents its most recent “Peer Exchange” panel discussion, “A Closer Look at Rare Neurological Diseases: Spinal Muscular Atrophy and Huntington’s Disease.” The video series features a multidisciplinary panel of experts who will discuss the burden, diagnosis, and management of these diseases. The panelists will also address new and emerging treatment options that could change the lives of patients living with Spinal Muscular Atrophy (SMA) and Huntington’s Disease.
“Rare diseases continue to be identified every year and present quite a challenge for scientists to stay up to date,” said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of AJMC®. “During this educational video series, our experts come together to address two rare diseases, Spinal Muscular Atrophy and Huntington Disease, and review some new exciting treatment options that could potentially help physicians when providing an adequate treatment plan for their patients with either disease.”
This AJMC® “Peer Exchange” panel features five distinguished experts:
- Dr. Peter L. Salgo, professor of medicine and anesthesiology at Columbia University College of Physicians and Surgeons and associate director of surgical intensive care at NewYork-Presbyterian Hospital, as moderator.
- Dr. John Brandsema, neuromuscular section head at Children’s Hospital of Philadelphia and assistant professor of clinical neurology at the University of Pennsylvania’s Perelman School of Medicine.
- Sika Dunyoh, director of education programs for the National Organization for Rare Disorders.
- Dr. Maria Lopes, former chief medical officer of Magellan Rx Management.
- Dr. Surya Singh, president at Singh Healthcare Advisors.
The Peer Exchange opens with an introduction to rare neurological diseases and an overview of the Orphan Drug Act. Throughout this series, experts discuss SMA, including its causes, symptoms, and types. Additionally, panel members contribute diverse perspectives to the diagnosis and management of SMA, as well as novel treatment agents. These agents include Food and Drug Administration (FDA)-approved Nusinersen, newly FDA-approved gene replacement therapy Zolgensma, and pipeline agent, Risdiplam. The Peer Exchange series also reviews the signs, symptoms and emerging treatment options for patients with Huntington’s Disease.
For more information and to view the video series, click here.
About The American Journal of Managed Care®
The American Journal of Managed Care® (AJMC®) is a multimedia peer-reviewed, Medline-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision-makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care® and two evidence-based series, Evidence-Based Oncology™ and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Gil Hernandez at 609-716-7777, ext. 139.
609-716-7777, ext. 121